SecBot SecBot
SECBOTREPLAY Home › Report › PCRX

PCRX · Pacira BioSciences has agreed to sell its iovera handheld cryoanalgesia…

Pacira BioSciences, Inc. · 8-K filed Jun 30, 2026 at 07:31 ET

At the news

BULLISHIMPACT 7/10

8-K filed Jun 30, 2026 at 07:31 ET

Pacira BioSciences has agreed to sell its iovera handheld cryoanalgesia device business to Zimmer Biomet for up to $140M in total consideration ($70M upfront cash plus up to $70M in future revenue-based milestones). The deal includes collaboration on a spasticity program. Proceeds will be used to repay Pacira's senior secured revolving credit facility, strengthening its balance sheet. This divestiture advances Pacira's transition into a pure biopharmaceutical company focused on non-opioid therapies.

  • Pacira to receive $70M upfront cash for the iovera divestiture to Zimmer Biomet
  • Total potential consideration up to $140M including $70M in revenue-based milestone payments through 2031
  • Upfront proceeds to be used to pay down Pacira's senior secured revolving credit facility
  • 66 employees (~8% of workforce) expected to transfer to Zimmer Biomet at closing

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access